HX531

HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities.


Cat. No.: EX-A14221	Purity: >98%

	Chemical structure of HX531

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	578	In-stock
250mg	978	In-stock
500mg	1578	In-stock
1g	2378	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	HX 531
CAS No.	188844-34-0
Purity	>98%
Formula	C29H29N3O4
Mol Weight	483.5583
Color	Light yellow to orange
State	Solid
Solubility	DMSO : 33.33 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years; In solvent -20°C, 1 month.
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Konta T, et al. Selective roles of retinoic acid receptor and retinoid x receptor in the suppression of apoptosis by all-trans-retinoic acid. J Biol Chem. 2001 Apr 20;276(16):12697-701. [2]. Yamauchi T, et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest. 2001 Oct;108(7):1001-13. [3]. Atsuko Nakatsuka, et al. RXR antagonism induces G0 /G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21(Cip1) pathway in adipocytes. J Pathol. 2012 Apr;226(5):784-95. [4]. Wenrui Zhao, et al. RXR signaling targeted cancer therapy. January 2023The Innovation Life 1(1):100014
CoA	CoA of HX531

Smiles:	CC1(CCC(C2=C1C=C3C(=C2)N(C4=C(C=C(C=C4)[N+](=O)[O-])N=C3C5=CC=C(C=C5)C(=O)O)C)(C)C)C


		Search